Navigation Links
Acclarent, Inc. Closes $26 Million Financing
Date:1/11/2009

MENLO PARK, Calif., Jan. 12 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat, announced today the closing of a $26 million dollar financing round. Acclarent intends to use the proceeds to continue commercialization of its Balloon Sinuplasty(TM) Technology, as well as on-going investment in product development and clinical studies.

Johnson & Johnson Development Corporation (JJDC) joined existing prominent investors New Enterprise Associates, Inc., Delphi Ventures, Versant Ventures, and Meritech Capital Partners in this financing.

"The addition of JJDC together with the support of our existing financial partners will enable Acclarent to continue executing on our strategy to build the preeminent ENT Company," said Bill Facteau, Acclarent President and CEO.

About Johnson & Johnson Development Corporation. Organized in 1973, Johnson & Johnson Development Corporation is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies. For more information, go to http://www.jjdevcorp.com.

About Acclarent, Inc.

Acclarent is a medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat. The company is currently focused on commercializing its Balloon Sinuplasty(TM) Devices, which are flexible, minimally-invasive tools that aid physicians in treating patients suffering from chronic sinusitis.


'/>"/>
SOURCE Acclarent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
2. Pioneer(R) Surgical Technology, Inc. Closes $15 Million Series B Financing
3. Rcadia Medical Imaging Closes $3.3 Million Investment Led by BioVentures Investors
4. Oaks Development Group Closes on Third San Antonio Project
5. Cardiome Discloses Chairman And CEOs Involuntary Share Sale
6. Morgenthaler Closes Ninth Fund at $400 Million
7. Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials
8. Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant
9. Response Biomedical Closes $5.1 Million Financing
10. Blue Cross Blue Shield of Michigan Closes Detroit Operations October 31 Due to Bomb Threat
11. Oaks Development Group Closes on 2.1 Acres for Medical Office Building in Palm Coast, FL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... NJ (PRWEB) , ... April 26, 2017 , ... RawTrition ... an easy way to get nutrients from SUPERFOODS! , RawTrition is taking ... at the cellular level because the body recognizes its raw form (unlike the synthetically ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring ... birth defects research related to Zika virus during pregnancy, as well as other ... this important science. , The Teratology Society is an international ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... -- Viverae ® , a leader in workplace wellness ... ® Watson Campaign Automation, implementing behavioral messaging within ... personalized experience. Through digital engagement, the platform prompts members ... time. The enhanced experience drives engagement by focusing on ... are in their journey to health. ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc. and ... started in 2016, in which Socionext extracts and ... The companies achieved initial results in reading ultrasound ... Artificial Brain SOINN. The results will be introduced ... April 19-21, at booths 4505 & 4507. ...
Breaking Medicine Technology: